DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the GLAXOSMITHKLINE PHARMA LT (GLAXO) share price today?

GLAXOSMITHKLINE PHARMA LT (GLAXO) is trading at ₹2,454.8 on the NSE, down 2.05% on the day. Source: DocStoX.

What is the PE ratio of GLAXOSMITHKLINE PHARMA LT?

GLAXOSMITHKLINE PHARMA LT has a price-to-earnings (PE) ratio of 40.1 in the Healthcare sector.

What is the market capitalisation of GLAXOSMITHKLINE PHARMA LT?

GLAXOSMITHKLINE PHARMA LT has a market capitalisation of approximately ₹41,591 crore.

GLAXOSMITHKLINE PHARMA LT

GLAXO·NSE·Healthcare

₹2,454.80▼ -51.50 (-2.05%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY MIDCAP 150

Day₹2430.00

₹2510.60

52W₹2088

₹322032%

Open

₹2506.30

High

₹2510.60

Low

₹2430.00

Prev Close

₹2506.30

Volume

56.2K

VWAP

₹2453.08

Snapshot

Key fundamentals

Market Cap

₹41,591 Cr

P/E Ratio

40.14Expensive

P/B Ratio

18.25

EPS

₹61.15

Book Value

₹134.00

ROE

45.60%Strong

ROCE

61.00%Efficient

Dividend Yield

2.34%

Debt / Equity

0.01Low

Face Value

₹10.00

52W High

₹3220.00

52W Low

₹2088.10

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹329

▼ 86.6%downside

Trading at ₹2,455 — 87% above our estimate

BearFair valueBull

₹280₹329₹429

/100

Business quality — Solid

Growth 50Profitability 100Efficiency 50Valuation 62

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Strong returns on equity (46%)
Capital is working hard (ROCE 61%)
Profit growing 19% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

46% ROE fading to 12% over ~10 yrs, on ₹134 book

₹301

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹429

Analyst target

No analyst coverage

—

Blended fair value₹329

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (46%)
Capital is working hard (ROCE 61%)
Profit growing 19% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

40.1Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

45.6%Strong

Above 15% is considered healthy for Indian equities

ROCE

61.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹41,591 Cr

P/B

18.25

EPS

₹61.15

Div Yield

2.34%

What changed

Recent changes

Foreign investors+0.2% stake last quarter
Domestic institutions+0.1% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 40.1×

Growth

Steady

+6% rev CAGR

Profitability

Excellent

45.6% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %53.9%

Turnover₹1377.55L Cr

Trades12,304

VWAP₹2453.08

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+5.5%

10Y

+3.0%

Profit

+19.2%

+23.7%

10Y

+10.7%

EPS

+19.3%

+23.7%

10Y

+10.7%

Profile

Pros

Company is almost debt free.
Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
Company has been maintaining a healthy dividend payout of 94.6%

Watch-outs

Cons

Stock is trading at 18.2 times its book value
The company has delivered a poor sales growth of 5.49% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 0.17 pts; domestic institutions added 0.13 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

75.0%0.00

Public

12.4%-0.27

FII / FPI

4.8%+0.17

DII

7.8%+0.13

Quarterly trend

Ownership over time

Q1 FY27

Promoter75.00%

FII4.79%

DII7.81%

Public12.42%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)